Analytical Data
-
Gene name
Defb14
- Application
-
Alternative Names
Defensin, beta 14
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q7TNV9
-
Expression Region
23-67aa
-
Molecular Weight
21.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Defb14, a member of the defensin family of antimicrobial peptides, plays a crucial role in the immune response of various species, particularly in the context of innate immunity. Originally identified in mice, Defb14 exhibits broad-spectrum antimicrobial properties, which are vital for protecting against bacterial, viral, and fungal infections. The peptide is primarily expressed in the skin, respiratory tract, and other epithelial tissues, where it acts as a first line of defense by disrupting microbial membranes and modulating inflammatory responses. Recent studies have highlighted the significance of Defb14 in wound healing and its potential therapeutic applications in treating infections, particularly in antibiotic-resistant strains. Research on the recombinant expression of Defb14 aims to elucidate its structural characteristics, functional mechanisms, and interactions with pathogens. By producing Defb14 in a laboratory setting, scientists hope to explore its potential uses in medical therapies, vaccine development, and as a novel antimicrobial agent. As the field of immunology continues to advance, understanding the role of Defb14 and optimizing its recombinant production could lead to innovative strategies for combating infectious diseases and enhancing immune responses in humans and animals.
